CP-075 Prognostic factors in patients with recurrent epithelial ovarian cancer

BackgroundPegylated liposomal doxorubicin (PLD) is indicated in ovarian cancer patients who have failed firstline platinum based chemotherapy. Currently, there are no clinical or biomolecular factors that can predict the benefit of PLD in this population.PurposeTo identify clinical predictors of ove...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A33-A33
Main Authors: Palomo, A Rodriguez, Manceñido, FJ Alvarez, García, I Zapico, Lorenzo, L Sanchez, Villanueva, P Pena, Bayonas, A Carmona, Canovas, M Sanchez, Faez, L, Solis, MP, Fonseca, P Jimenez
Format: Article
Language:English
Subjects:
Chemotherapy
Medical prognosis
Ovarian cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundPegylated liposomal doxorubicin (PLD) is indicated in ovarian cancer patients who have failed firstline platinum based chemotherapy. Currently, there are no clinical or biomolecular factors that can predict the benefit of PLD in this population.PurposeTo identify clinical predictors of overall survival (OS) in patients with recurrent ovarian cancer treated with PLD.Material and methods9 baseline variables were evaluated to assess its prognostic ability in 143 patients treated with PLD from January 2008 to January 2014. The analysed variables were: Eastern Cooperative Group Performance Status (ECOG-PS), age, histopathology, treatment line, platinum sensitivity (progression free interval(PFI)) and chemotherapy schedule (monotherapy vs polychemotherapy). Cox regression models were used to calculate the log hazard ratio, and the most parsimonious model was selected according to the Akaike information criteria.ResultsThe prognostic index includes four variables associated with OS: ECOG-PS (>70), age (≤70 years), platinum highly sensitive (PFI ≥12 months after completion of frontline platinum based chemotherapy) and use of combination chemotherapy (PLD and carboplatinum/gemcitabine/trabectidin were assigned 2 points and intermediately sensitive (PFI 6–12 months) was assigned 1 point). The global median progression free survival for all patients was 5.9 months (95% CI 4.0–7.3) and median OS was 18.8 months (95% CI 15.2–23.3). The score had the potential to delineate five prognostic groups whose results are shown in the table.PointMedian95% CICoefHR95% CIp Value 06.54.9–11.4---112.02.0–15.2-0.6790.500.19–1.340.1758217.713.7–25.5-1.3450.260.10–0.640.0036335.115.0–41.1-2.0960.120.04–0.340.0001435.328.9–51.5-2.2190.100.04–0.28
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2017-000640.74